Trial Profile

Long-term extension safety and efficacy study of SAR442168 in participants with relapsing multiple sclerosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tolebrutinib (Primary)
Indications Multiple sclerosis
Focus Adverse reactions
Sponsors Sanofi; Sanofi Genzyme

Most Recent Events

27 Dec 2024 Status changed from active, no longer recruiting to completed.
23 Sep 2024 This trial has been completed in Estonia, according to European Clinical Trials Database record.
13 Oct 2023 Results assessing magnetic resonance imaging (MRI)outcomes at Week (W) 144 presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com